OTCPK:MGFR.F

Stock Analysis Report

Executive Summary

MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland.


Snowflake Analysis

Exceptional growth potential and slightly overvalued.

Share Price & News

How has MagForce's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MGFR.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

MGFR.F

10.2%

US Medical Equipment

9.4%

US Market


1 Year Return

n/a

MGFR.F

2.1%

US Medical Equipment

-6.8%

US Market

Return vs Industry: Insufficient data to determine how MGFR.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how MGFR.F performed against the US Market.


Shareholder returns

MGFR.FIndustryMarket
7 Day0%10.2%9.4%
30 Dayn/a0.9%-3.9%
90 Dayn/a-12.1%-16.5%
1 Yearn/a2.9%2.1%-4.8%-6.8%
3 Yearn/a57.1%52.9%23.4%15.2%
5 Year-42.0%-42.0%89.2%69.8%41.3%25.7%

Price Volatility Vs. Market

How volatile is MagForce's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MagForce undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MGFR.F ($3.3) is trading below our estimate of fair value ($18.51)

Significantly Below Fair Value: MGFR.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MGFR.F is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: MGFR.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MGFR.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MGFR.F is overvalued based on its PB Ratio (4.1x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

65.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGFR.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: MGFR.F is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MGFR.F's is expected to become profitable in the next 3 years.

Revenue vs Market: MGFR.F's revenue (50.9% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: MGFR.F's revenue (50.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MGFR.F's Return on Equity is forecast to be very high in 3 years time (50.8%).


Next Steps

Past Performance

How has MagForce performed over the past 5 years?

-6.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MGFR.F is currently unprofitable.

Growing Profit Margin: MGFR.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MGFR.F is unprofitable, and losses have increased over the past 5 years at a rate of -6.9% per year.

Accelerating Growth: Unable to compare MGFR.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MGFR.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).


Return on Equity

High ROE: MGFR.F has a negative Return on Equity (-25.54%), as it is currently unprofitable.


Next Steps

Financial Health

How is MagForce's financial position?


Financial Position Analysis

Short Term Liabilities: MGFR.F's short term assets (€3.8M) exceed its short term liabilities (€3.4M).

Long Term Liabilities: MGFR.F's short term assets (€3.8M) do not cover its long term liabilities (€16.9M).


Debt to Equity History and Analysis

Debt Level: MGFR.F's debt to equity ratio (89.2%) is considered high.

Reducing Debt: Insufficient data to determine if MGFR.F's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if MGFR.F has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MGFR.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is MagForce's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MGFR.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MGFR.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MGFR.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGFR.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MGFR.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.5yrs

Average management tenure


CEO

Ben Lipps (79yo)

6.58s

Tenure

Dr. Benjamin J. Lipps, also known as Ben, has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG since September 1, 2013. Dr. Lipps served as the Chief Executive Officer a ...


Leadership Team

NamePositionTenureCompensationOwnership
Benjamin Lipps
Chairman of the Management Board & CEO6.58yrsno datano data
Andreas Jordan
Founder & Advisorno datano datano data
Christian Von Volkmann
CFO & Member of Management Board7.5yrsno datano data
Hoda Tawfik
Chief Medical Officer & Member of Management Board7.5yrsno datano data
Barbara Frankenberg
Vice President of Communications & Investor Relations4.08yrsno datano data
Solveig Salomon
VP of Marketing & Sales and European Commercial Directorno datano datano data
Hans Hutt
Medical Consultant9.42yrsno datano data

7.5yrs

Average Tenure

62yo

Average Age

Experienced Management: MGFR.F's management team is seasoned and experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.


Top Shareholders

Company Information

MagForce AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MagForce AG
  • Ticker: MGFR.F
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €71.865m
  • Listing Market Cap: €78.584m
  • Shares outstanding: 27.64m
  • Website: https://www.magforce.com

Number of Employees


Location

  • MagForce AG
  • Max-Planck-Strasse 3
  • Berlin
  • Berlin
  • 12489
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MF6DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2007
MF6XTRA (XETRA Trading Platform)YesCommon StockDEEURSep 2007
MGFR.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2007
0W10LSE (London Stock Exchange)YesCommon StockGBEURSep 2007

Biography

MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing superparamagnetic iron oxide nano-particles that can be activated in an alternative magnetic field; NanoPlan, a therapy planning software; and NanoActivator, a magnetic field applicator. The company was founded in 1997 and is headquartered in Berlin, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/10 00:10
End of Day Share Price2020/03/24 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.